175 related articles for article (PubMed ID: 24730531)
1. Pleiotropic effects of platelet P2Y12 receptor inhibitors: fact or fiction?
Moulias A; Xanthopoulou I; Alexopoulos D
Curr Pharm Des; 2014; 20(28):4597-604. PubMed ID: 24730531
[TBL] [Abstract][Full Text] [Related]
2. P2Y12 receptor antagonists in acute coronary syndrome: clinical implications of pharmacologic and pharmacogenetic differences.
Singh M; Adigopula S; Ahmad N; Arora R; Khosla S
Recent Pat Cardiovasc Drug Discov; 2011 Sep; 6(3):207-14. PubMed ID: 21861826
[TBL] [Abstract][Full Text] [Related]
3. Platelet Inhibition Agents: Current and Future P2Y12 Receptor Antagonists.
Tang J; Li MP; Zhou HH; Chen XP
Curr Vasc Pharmacol; 2015; 13(5):566-77. PubMed ID: 25440595
[TBL] [Abstract][Full Text] [Related]
4. The Rationale for and Clinical Pharmacology of Prasugrel 5 mg.
Jakubowski JA; Erlinge D; Alexopoulos D; Small DS; Winters KJ; Gurbel PA; Angiolillo DJ
Am J Cardiovasc Drugs; 2017 Apr; 17(2):109-121. PubMed ID: 27854064
[TBL] [Abstract][Full Text] [Related]
5. P2Y12 platelet receptors: importance in percutaneous coronary intervention.
Falcão FJ; Carvalho L; Chan M; Alves CM; Carvalho AC; Caixeta AM
Arq Bras Cardiol; 2013 Sep; 101(3):277-82. PubMed ID: 23917456
[TBL] [Abstract][Full Text] [Related]
6. Genotype-guided treatment of oral P2Y
Claassens DM; Ten Berg JM
Pharmacogenomics; 2020 Jan; 21(2):83-86. PubMed ID: 31957547
[No Abstract] [Full Text] [Related]
7. [Recent advances on the studies of the platelet's inhibition and aggregation. State of the art of new P2Y12 antagonists].
Cattaneo GJ; Podda GM; Cattaneo M
Recenti Prog Med; 2011 Apr; 102(4):150-5. PubMed ID: 21572491
[TBL] [Abstract][Full Text] [Related]
8. Clinical effects and outcomes with new P2Y12 inhibitors in ACS.
Collet JP; O'Connor S
Fundam Clin Pharmacol; 2012 Feb; 26(1):16-8. PubMed ID: 21895760
[TBL] [Abstract][Full Text] [Related]
9. Impact of tailored anti-P2Y12 therapies in acute coronary syndromes.
Stimpfle F; Geisler T
Pharmacogenomics; 2015; 16(5):493-9. PubMed ID: 25916521
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous Platelet P2Y12 and P2Y1 ADP Receptor Blockade: Are Two Better Than One?
Vaduganathan M; Bhatt DL
Arterioscler Thromb Vasc Biol; 2016 Mar; 36(3):427-8. PubMed ID: 26912743
[No Abstract] [Full Text] [Related]
11. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.
Winter MP; Grove EL; De Caterina R; Gorog DA; Ahrens I; Geisler T; Gurbel PA; Tantry U; Navarese EP; Siller-Matula JM
Eur Heart J Cardiovasc Pharmacother; 2017 Oct; 3(4):221-234. PubMed ID: 28204303
[TBL] [Abstract][Full Text] [Related]
12. A critical appraisal of the functional evolution of P2Y12 antagonists as antiplatelet drugs.
Fayaz SM; Rajanikant GK
Curr Pharm Des; 2012; 18(12):1625-34. PubMed ID: 22360514
[TBL] [Abstract][Full Text] [Related]
13. Switching P2Y12-receptor inhibitors in patients with coronary artery disease.
Rollini F; Franchi F; Angiolillo DJ
Nat Rev Cardiol; 2016 Jan; 13(1):11-27. PubMed ID: 26283269
[TBL] [Abstract][Full Text] [Related]
14. Will this trial change my practice? ACCOAST - early loading with a novel P2Y12 inhibitor in patients with an acute coronary syndrome.
De Palma R; James S; Jüni P; Cuisset T
EuroIntervention; 2014 Jul; 10(3):408-10. PubMed ID: 25042271
[No Abstract] [Full Text] [Related]
15. Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE).
Alexopoulos D; Goudevenos JA; Xanthopoulou I; Deftereos S; Sitafidis G; Kanakakis I; Hamilos M; Parissis H; Ntalas IV; Angelidis C; Petousis S; Vavuranakis M; Hahalis G; Stefanadis C;
Int J Cardiol; 2013 Oct; 168(6):5329-35. PubMed ID: 23978364
[TBL] [Abstract][Full Text] [Related]
16. Laboratory monitoring of P2Y
Frelinger AL; Gachet C; Mumford AD; Noris P; Mezzano D; Harrison P; Gresele P;
J Thromb Haemost; 2018 Nov; 16(11):2341-2346. PubMed ID: 30284374
[No Abstract] [Full Text] [Related]
17. Ticagrelor-associated bleeding in a patient undergoing surgery for acute type A aortic dissection.
Dalén M; Ivert T; Lindvall G; van der Linden J
J Cardiothorac Vasc Anesth; 2013 Oct; 27(5):e55-7. PubMed ID: 23921293
[No Abstract] [Full Text] [Related]
18. Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Uhry S; Bessereau J; Camoin-Jau L; Paganelli F; Bonello L
Hosp Pract (1995); 2012 Apr; 40(2):104-17. PubMed ID: 22615085
[TBL] [Abstract][Full Text] [Related]
19. P2Y12 inhibitors in acute coronary syndrome: when to give them and when to prolong their use.
Grotti S; Bolognese L
J Cardiovasc Med (Hagerstown); 2018 Feb; 19 Suppl 1():e9-e12. PubMed ID: 29538137
[No Abstract] [Full Text] [Related]
20. Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
Aradi D; Komócsi A; Vorobcsuk A; Serebruany VL
Thromb Haemost; 2013 Jan; 109(1):93-101. PubMed ID: 23197191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
